PALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
– Zero HIV Acquisitions Occurred Among Participants Receiving Twice-Yearly Lenacapavir During the 52-Week Study Period –
– PURPOSE 5 Study Findings Highlight the Potential of Long-Acting HIV Prevention Option to
- Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or with Intolerance to
NEW YORK, Nov. 4, 2026 /CNW/ -- Fly on Wall Street News Commentary - Wall Street's major indexes rallied together on Wednesday. As of 2:31 p.m. ET, the Dow Jones Industrial Average was up 1,552.12 points, or 3.0%,
– iMMagine-1 Data Provide 18 Months Minimum Follow-Up on Anito-cel’s Durability and Safety in Relapsed or Refractory Multiple Myeloma –
– Five-Year ZUMA-12 Follow-Up Data to Provide Long-Term Evidence for Yescarta®
– Results Highlight the Potential of Long-Acting Regimens, Including Twice-Yearly and Once-Weekly Options, to Transform the Treatment and Prevention of HIV –
Gilead Sciences, Inc. (NASDAQ:GILD) today announced its
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS
Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion
Biktarvy Sales Increased 10% Year-Over-Year to $4.1 Billion
Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations
Successful completion of pan-Canadian negotiations paves the way for provinces and territories to publicly fund an innovative therapy for primary biliary cholangitis (PBC)MISSISSAUGA, ON, Oct. 27, 2026 /CNW/ --
PALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio --
-- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead
- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Cholangitis (PBC)
– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment –
– Real-World Evidence Provides Insight into Early U.S. Adoption of
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day,
- 6 Royalty-Free Voluntary Licensing Agreements Aim to Support Potential Manufacturing Readiness and Supply in 120 High-Incidence, Resource-Limited Countries Ahead of Phase 3 PURPOSE 365 Results and Potential
